

Date: 13th November, 2021

To, Listing Department, BSE Limited, Floor 25, PJ Tower Dalal Street, Mumbai – 400 001 Script Code: 540359

Sub.: Outcome of the meeting of the Board of Directors of the Company

Dear Sirs,

In continuation of our Corporate announcement dated 3rd November, 2021 we hereby inform you that the Board of Directors of the Company has, at its meeting held today, inter—alia, considered and approved:

i. Unaudited Financial Results for quarter and half year ended 30th September, 2021. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and half year ended 30th September, 2021.

Further we are submitting the Limited Review report on 0Unaudited Financial Results for quarter and half year ended $30^{\rm th}$ September, 2021issued by our Statutory Auditors i.e. M/ s. B A Shah S R Mehta & Co.

The meeting was concluded at 7:15 pm.

Kindly take this on your records.

Thanking you,

Yours faithfully,

For, Parmax Pharma Limited

Yash J. Vora Company Secretary

Encl: As above

PARMAX PHARMA LIMITED

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504



				V		8 6 9	(in Rs.
r.	Particulars -	Quarter Ended			Half Year Ended		Year Ended
о.		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
ı	Revenue from operations	65424425	17348202	60892852	82772627	83624177	26204544
- 1	Other income	246515	157580	306613	404095	421877	88860
- 1	Total Income (I+II)	65670940	17505782	61199465	83176722	84046054	26293409
_ H	Expenses	03070340	17303702	01133 103			
	(a) Cost of materials consumed	13679199	8110278	23671263	21789477	48449518	1341178
- 1	(b) Purchase of stock-in-trade	0	-	0	0	0) ASSESSMENT OF THE PROPERTY O
	(b) Furchase of stock-in-trade	Ü					
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	11047511	-9261958	8556428	1785553	-7997192	2310
	(d) Employee benefits expense	12021927	8118977	8156031	20140904	16402037	353887
- 1	(e) Finance Costs	994177	933464	916846	1927641	1830414	3542515.
	(f) Depreciation and amortisation expense	4768281	4709329	4857728	9477610	9226391	194156
- 1	(g) Other expenses		9246562		21000139	20927119	581538
- 1		11753577		9873220	76121324	88838287	
- 1	Total expenses (IV)	54264672	21856652	56031516	76121324	00030207	2308430
- 1	Profit/(Loss) from operations before	11406268	-4350870	5167949	7055398	-4792233	120843
	exceptional items and tax (I-IV)	11100200			W 5 W 5 W		
	Exceptional Items	0	0	0	0	0	
	Profit/ (Loss) before tax (V-VI)	11406268	-4350870	5167949	7055398	-4792233	120843
II	Tax expense:						
	(1) Current tax	0	0	0	0	C	
	(2) Deferred tax	0	0	0	0	C	15839
	Net Profit / (Loss) for the period from	11400200	4250970	5167949	7055398	-4792233	75442
	continuing operations (VII-VIII)	11406268	-4350870	510/949	7033398	-4732233	7,5442
	Profit/(loss) from discontinued operations		0		4		
	Tax expense of discontined operations	0	0	0	. 0	C	
	Profit/(loss) from Discontined operations	0	0	0	0		
I	(after tax) (X-XI)	0	0	U	U		
II	Profit (Loss) for the period (IX+XII)	11406268	-4350870	5167949	7055398	-4792233	7544
	Other Comprehensive Income		=				
	A. (i) Items that will not be reclassifled to profit		8		N.		
	or loss				_		-
	(ii) Income tax relating to items that will not be	_			-#		
V	reclassified to profit or loss	0	0	0	0	(
	B. (i) Items that will be reclassified to profit or	9)	00				
	loss						
	(ii) Income tax relating to items that will be						
	reclassified to profit or loss		1 1				

	Total Comprehensive Income for the period			129 22200		470000	7544
V	(XIII+XIV) Comprising Profit (Loss) and Other	11406268	-4350870	5167949	7055398	-4792233	7544
	comprehensive Income for the period)		1				
/ I	Paid-up equity share capital (Face Value Rs	37413000	37413000	37413000	37413000	37413000	37413
107	10)	77.35		- American September 1			
VII	Earnings per share (for continuing operation					×	
	& discontinuing operation)						1
	(of Rs. 10/- each):	950.54000.00	22.22.22.22		app research		
	(a) Basic	3.05	-1.16	1.38	1.89	-1.23	3

PARMAX PHARMA LIMITED

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot 31 Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504

Mfg. of : Bulk Drugs, Drug Intermediates & Speciality Chemicals



Notes:

- 1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 13.11.2021.
- 2. The Stautory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and half year ended 30th September, 2021
- 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
- 4. Statement of Unaudited Financial Results of the company for the Quarter and half ended 30th September, 2021, in the prescribed format under Schedule III of Companies Act, 2013
- 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-oprative expenses which are forming the part of Balance Sheet accordingly Company has writen off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

FOR, PARMAX PHARMA LIMITED

Place Hadamtala (Rajkot)

Date: 13.11.2021

Dr. Umang Gosalia Managing Director

PARMAX PHARMA LIMITED

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504



STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09,2021

(g) Biological Assets of (h) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (i) Deferred tax asset (j) Other non-current 2 Current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be specification of the current assets (d) Other Equity (a) Equity Share cap (b) Other Equity Total Equity LIABILITIES (a) Financial Liabiliti (i) Borrowings (ii) Trade payables	turi.	(Unaudited)	(Audited)
(a) Property, Plant an (b) Capital work-in-pr (c) Investment Proper (d) Goodwill (e) Other Intangible a (f) Intangible assets u (g) Biological Assets of (h) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (i) Deferred tax asset (j) Other non-current (ii) Trade receivables (iii) Trade receivables (iv) Bank balances of (v) Loans (vi) Others (to be specific to be specific t			-
(b) Capital work-in-pr (c) Investment Proper (d) Goodwill (e) Other Intangible a (f) Intangible assets u (g) Biological Assets c (h) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (i) Deferred tax asset (j) Other non-current (ii) Trade receivables (iii) Investments (ii) Investments (ii) Trade receivables (iii) Trade receivables (iv) Bank balances ot (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass (d) Other current ass (d) Other current liabiliti (a) Equity Total Equity Total Equity Total Equity Total Equity Total Equity (a) Equity Share cap (b) Other Equity Total Equity (a) Equity Share cap (b) Other financial Liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (ii) Borrowings		100007711	108431440
(c) Investment Proper (d) Goodwill (e) Other Intangible as (f) Intangible assets u (g) Biological Assets of (h) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (i) Deferred tax asset (j) Other non-current Current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be specification of the companion of the co	at and Equipment	100867714	
(d) Goodwill (e) Other Intangible as (f) Intangible assets u (g) Biological Assets of (h) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (i) Deferred tax asset (j) Other non-current Current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash ectivity Bank balances of (v) Loans (vi) Others (to be specification of the company of the compa	n-progress	0	
(e) Other Intangible a (f) Intangible assets u (g) Biological Assets o (h) Financial Assets (ii) Investments (iii) Loans (i) Deferred tax asset (j) Other non-current Current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current asset I. EQUITY AND LIABIL Equity (a) Equity Share cap (b) Other Equity Total Equity Total Equity Investments (ii) Trade receivables (iii) Other financial Liabiliti (j) Borrowings (iii) Trade payables (iiii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-current ii. Current liabilities (a) Financial Liabilities	operty	0	
(f) Intangible assets u (g) Biological Assets of (h) Financial Assets (ii) Investments (iii) Trade receivables (iii) Loans (i) Deferred tax asset (j) Other non-current Current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be specification of the companion of the companio		0	
(g) Biological Assets of (h) Financial Assets (ii) Investments (ii) Trade receivables (iii) Loans (i) Deferred tax asset (j) Other non-current (a) Investments (ii) Trade receivables (iii) Cash and cash ed (iv) Bank balances of (v) Loans (vi) Others (to be specification of the company of the	ble assets	0	
(h) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (i) Deferred tax asset (j) Other non-current Current assets (a) Inventories (b) Financial Assets (ii) Trade receivables (iii) Trade receivables (iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass I. EQUITY AND LIABIL I Equity (a) Equity Share cap (b) Other Equity Total Equity Total Equity I Total Equity I HABILITIES I Non-current liabiliti (i) Borrowings (iii) Trade payables (iiii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-current ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities	ets under development	C	
(h) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (i) Deferred tax asset (j) Other non-current Current assets (a) Inventories (b) Financial Assets (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass I. EQUITY AND LIABIL LEQUITY AND LIABIL LEQUITY Capacity Total Equity (a) Equity Share cap (b) Other Equity Total Equity Total Equity (a) Financial Liabiliti (i) Borrowings (iii) Trade payables (iiii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-current iii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities	ets other than bearer plants	0	
(ii) Trade receivables (iii) Loans (i) Deferred tax asset (j) Other non-current Current assets (a) Inventories (b) Financial Assets (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass I. EQUITY AND LIABIL I Equity (a) Equity Share cap (b) Other Equity Total Equity Total Equity I IABILITIES i. Non-current liabiliti (i) Borrowings (iii) Trade payables (iiii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (d) Other non-current iii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities			
(iii) Loans (i) Deferred tax asset (j) Other non-current Current assets (a) Inventories (b) Financial Assets (ii) Investments (iii) Trade receivables (iii) Cash and cash ec (iv) Bank balances ot (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass (d) Other current ass (a) Equity Share cap (b) Other Equity Total Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-current ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities		6000	200600
(i) Deferred tax asset (j) Other non-current Current assets (a) Inventories (b) Financial Assets (ii) Investments (iii) Trade receivables (iii) Cash and cash ec (iv) Bank balances ot (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass I. EQUITY AND LIABIL I Equity (a) Equity Share cap (b) Other Equity Total Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (a) Financial Liabiliti (i) Borrowings (iii) Trade payables (iiii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities	bles	(
(i) Deferred tax asset (j) Other non-current (ii) Other non-current (iii) Financial Assets (iii) Investments (iii) Trade receivables (iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass (d) Other current ass (iii) Equity Share cap (b) Other Equity Total Equity Total Equity 2 LIABILITIES (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre (ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities		2019531.27	156669
(j) Other non-current (a) Current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances ot (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass (d) Other current ass (e) Equity (a) Equity Share cap (b) Other Equity Total Equity Total Equity (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre (ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities	ssets (net))
E Current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances ot (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass II. EQUITY AND LIABIL 1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities		9903497	
(a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances ot (v) Loans (vi) Others (to be spo (c) Current Tax Asset (d) Other current ass II. EQUITY AND LIABIL 1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (i) Borrowings	Total Non-Current Asset	112796742	12388833
(a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances ot (v) Loans (vi) Others (to be spo (c) Current Tax Asset (d) Other current ass II. EQUITY AND LIABILI 1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities			
(b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances ot (v) Loans (vi) Others (to be spo (c) Current Tax Asset (d) Other current ass II. EQUITY AND LIABIL 1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (ii) Borrowings		28018599	3953139
(i) Investments (ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass II. EQUITY AND LIABIL 1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (d) Financial Liabilities (d) Other non-curre	ets		
(ii) Trade receivables (iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass II. EQUITY AND LIABIL 1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities			O
(iii) Cash and cash ec (iv) Bank balances of (v) Loans (vi) Others (to be spe (c) Current Tax Asset (d) Other current ass II. EQUITY AND LIABIL 1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (d) Other non-curre	bles	4335794	7 1654252
(iv) Bank balances of (v) Loans (vi) Others (to be specification of the second of the		54026	7 2546447
(v) Loans (vi) Others (to be specific to be specific) Current Tax Asset (d) Other current asset (d) Other current asset (d) Other current asset (a) Equity AND LIABIL 1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-current ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities			D
(vi) Others (to be spot (c) Current Tax Asset (d) Other current asset (d) Other current asset (d) Other current asset (d) Other current asset (e) Other Equity (a) Equity Share cap (b) Other Equity Total Equity Total Equity 2 LIABILITIES (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-current (d) Other non-current (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities (b) Borrowings	es other than(iii) above	1087746	2 2185451
(c) Current Tax Asset (d) Other current ass (d) Other current ass (d) Other current ass (e) Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre (d) Other non-curre (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities (b) Forowings			0
(d) Other current as: Compared to the compa			0
II. EQUITY AND LIABIL 1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (i) Borrowings (ii) Trade payables (iii) Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabilities (a) Financial Liabilities (b) Financial Liabilities (c) Financial Liabilities (d) Financial Liabilities		243243.6	1
1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings	it assets Tatal Current Asset		
1 Equity (a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings	Total Asse		
(a) Equity Share cap (b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings	ABILITIES		
(b) Other Equity Total Equity 2 LIABILITIES i. Non-current liabiliti (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings			
Total Equity LIABILITIES Non-current liabiliti (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings	capital	4451150	
2 LIABILITIES i. Non-current liabiliti (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings		2072806	
2 LIABILITIES i. Non-current liabiliti (a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings		6523956	8 5818410
(a) Financial Liabiliti (i) Borrowings (ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti			200,00
(i) Borrowings (ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti	bilities		0
(i) Borrowings (ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti			0
(ii) Trade payables (iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings		6754891	1 543329
(iii)Other financial li (b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings	les		0
(b) Provisions (c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings	ial liabilities (other than those specified in item (b), to be specified		0
(c) Deferred tax liab (d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings	The state of the s		
(d) Other non-curre ii. Current liabilities (a) Financial Liabiliti (i) Borrowings	liabilities (Net)	230892	24 23089
ii. Current liabilities (a) Financial Liabiliti (i) Borrowings			0
(a) Financial Liabiliti (i) Borrowings	Total of Non-Current Liabiliti	es 13509740	566418
(a) Financial Liabiliti (i) Borrowings			
(i) Borrowings			0
	bilities		0
	No.	4680783	
		-103076.	0
	cial liabilities (other than those specified in item (c)	49970	
(b) Other current lia	nt liabilities		
(c) Provisions		89320	03/55
(d) Current Tax Liab	Liabilities (Net)		
	Total of Current Liabiliti	es 607368 1958342	

FOR, PARMAX PHARMA LIMITED

Place Hadamtala (Rajkot) Date: 13.11.2021

PARMAX PHARMA LIMITED aging Director

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail: info@parmaxpharma.com CIN: L24231GJ 1994PLC023504

Mfg. of: Bulk Drugs, Drug Intermediates & Speciality Chemicals



_	CASH FLOW STATEMENT FOR THE HALF				(Amt. Rs.)
	PARTICULARS	Half Year Period Ended on 30/09/2021	Half Year Period Ended on 30/09/2020	Period Ended on 31/03/2021	
			Unaudited	Unaudited	Audited
(<u>A)</u>	CASH FLOW FROM OPERATING ACTIVITIES				
	Net Profit After Extraordinary Item but Before Taxation:	ě	7,055,398	(4,792,227)	12,084,397
	Adjustments for:				
	Depreciation Depreciation		9,477,610	9,226,391	19,415,616
	Provision for Current Tax		-	-	2,956,207
	Provision for Deferred Tax Assets			°-	1,519,577
	Operating profit before Working Capital changes		16,533,008	4,434,164	28,543,806
	Adjustments for changes in Working Capital:		e 8		
	(Increase) / Decrease in Inventories		11,512,799	(20,687,607)	(12,292,771)
	(Increase) / Decrease in Trade & Other Receivables		(26,815,425)	(1,405,117)	16,503,729
	(Increase) / Decrease in Short term Loans and Advances		10,733,806	1,957,709	(5,370,545
	Increase / (Decrease) in Current Liabilities		(51,718,381)	22,319,795	2,482,867
			(51,710,501)		1,030,295
	Increase / (Decrease) in Tax Provisions		1,980,700	1,980,700	3,961,400
	(Increase) / Decrease in Non Current Assets (Increase) / Decrease in Long term Loans & Advances		(452,833)		
	Cash generated from Operations		(54,759,333)	4,159,218	6,707,838
	Net Cash from Operating activities	(A)	(38,226,325)	8,593,382	35,251,644
(B)	CASH FLOW FROM INVESTING ACTIVITIES			*	*
	Purchase of Fixed Assets		(1,913,884)	(19,054,618)	(31,459,603
	Net Cash from / (Used in) Investing activities	(B)	(1,913,884)	(19,054,618)	(31,459,603
(C)	CASH FLOW FROM FINANCING ACTIVITIES			V	
			12 215 007	1,684,231	3,997,562
	Increase / (Decrease) in other Long Term Borrowings (Increase)/ Decrease in Non Current Investment		13,215,997 2,000,000	1,064,231	-
	Net Cash (Used in) Financing activities	(C)	15,215,997	1,684,231	3,997,562
**	Net Increase in Cash & Cash Equivalents (A + B + C)		(24,924,213)	(8,777,005	7,789,602
	Cash & Cash Equivalents at the beginning of the year		25,464,479	17,674,876	17,674,877
	Cash & Cash Equivalents at the end of the year		540,266	8,897,871	25,464,479

FOR, PARMAX PHARMA LIMITED

HADAMTAL

Place Hadamtala (Rajkot) Date: 13.11.2021 Dr. Umang Gosalia Managing Director

PARMAX PHARMA LIMITED

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504

BASHAHSR MEHTA & Co.

Chartered Accountants

Partner Malay B Shah B.Com. F.C.A. M. No. 159526 Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To
The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of PARMAX PHARMA LTD ("the Company") for the quarter and half year ended 30th September 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on 13th November 2021. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there.

Head Office:

209-Sapphire Complex, IInd Floor 21/25-B New Jagnath Plot, Dr.Yagnik Road RAJKOT- 360 001 (GUJARAT) Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address: (0) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah 31@hotmail.com

BASHAHSRMEHTA & Co.

Chartered Accountants

Partner Malay B Shah B.Com. F.C.A. M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date: \3.11.2021

RAJKOT S R MEHTA

For B. A. SHAH S R MEHTA & Co.

Chartered Accountants

FRN NO: 128796W

MALAY B SHAH

Partner

M. No. 159526

UDIN: 21159526 AAAAR7605

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:

302-Vedant Complex, 7/B Kalpana Society, C.G.Road, Navrangpura, AHMEDABAD – 380 009 (GUJARAT) Electronic Address:

(0) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or

mbshah 31@hotmail.com